MedTrace Logo

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

NCT05394519 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2026-01-28

No results posted yet for this study

Summary

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.

The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Conditions

Interventions

DRUG

Cagrilintide

Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

DRUG

Semaglutide

Semaglutide administered subcutaneously (s.c., under the skin) once-weekly

DRUG

Placebo cagrilintide

Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

DRUG

Placebo semaglutide

Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-01-28
Completion
2025-02-03
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Canada
  • Germany
  • Hungary
  • India
  • Ireland
  • Japan
  • Malaysia
  • Poland
  • Puerto Rico
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05394519 on ClinicalTrials.gov